• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Section Contents Menu

Enforcement Actions

Nozin LLC

   

hhsbluebirdDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
  Silver Spring, MD 20903


From: FDA Center for Drug Evaluation and Research
(FDAFLUTASKFORCE-CDER@fda.hhs.gov)


Date: May 22, 2009


To: info@nozin.com


Nozin LLC
4608 North Park Avenue, 2nd Floor
Chevy Chase, MD 20815


Subject: Urgent Message from the Food and Drug Administration Regarding H1N1 Flu Virus-Related Products Marketed by Your Firm


UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
ROCKVILLE, MD 20903


TO: Nozin LLC/info@nozin.com
FROM: Food and Drug Administration
RE: Unapproved/Uncleared/Unauthorized Products Related to the H1N1 Flu Virus
DATE: May 22, 2009


WARNING LETTER


This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address 

http://nozin.com on May 14, 2009. The FDA has determined that your website offers a product for sale that is intended to diagnose, mitigate, prevent, treat or cure the H1N1 Flu Virus in people. This product has not been approved, cleared, or otherwise authorized by FDA for use in the diagnosis, mitigation, prevention, treatment, or cure of the H1N1 Flu Virus. This product is “Nozin.” The marketing of this product violates the Federal Food, Drug, and Cosmetic Act (FFDC Act). 21 U.S.C. §§ 331, 351, 352. We request that you immediately
cease marketing unapproved, uncleared, or unauthorized products for the diagnosis, mitigation, prevention, treatment, or cure of the H1N1 Flu Virus.


Some examples of the claims on your website include:


• “News events regarding the potential of a flu pandemic reinforce the importance of learning and practicing prevention. We, as the makers of the NOZIN® Nasal Sanitizer® product, have received many inquiries concerning the recent outbreak of the swine flu, a new strain of influenza A known as H1N1.
. . . .
Use of NOZIN® Nasal Sanitizer®, clinically shown to kill virus in the nose, is among the important steps you can take to help protect your health. Our web site contains detailed information such as the research behind the product, testimonials and a FAQ page.”


• “NOZIN® can boost defense against cold and flu germs anywhere.” 

 

The Secretary of Health and Human Services, under section 319 of the Public Health Service Act, 42 U.S.C. § 247d, has determined that a public health emergency exists nationwide involving the H1N1 Flu Virus that affects or has the significant potential to affect national security. Following this determination and in response to requests from the U.S. Centers for Disease Control and Prevention, FDA issued letters authorizing the emergency use of certain unapproved and uncleared products or unapproved or uncleared uses of approved or cleared products, provided certain criteria are met, under 21 U.S.C. § 360bbb-3. The marketing and sale of unapproved or uncleared H1N1 Flu Virus-related products that are not authorized by and used in accordance with the conditions of an Emergency Use Authorization, is a potentially significant threat to the public health. Therefore, FDA is taking urgent measures to protect consumers from products that, without approval or authorization by FDA, claim to diagnose, mitigate, prevent, treat or cure H1N1 Flu Virus in people.


You should take immediate action to ensure that your firm is not marketing, and does not market in the future, products intended to diagnose, mitigate, prevent, treat or cure the H1N1 Flu Virus that have not been approved, cleared, or authorized by the FDA. The above is not meant to be an all-inclusive list of violations. It is your responsibility to ensure that the products you market are in compliance with the FFDC Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that the claims you make for your products do not adulterate or misbrand the products in violation of the FFDC Act. 21 U.S.C. §§ 331, 351, 352. Within 48 hours, please send an email to FDAFLUTASKFORCE-CDER@fda.hhs.gov describing the actions that you have taken or plan to take to address your firm's violations. If your firm fails to take corrective action immediately, FDA may take enforcement action, such as seizure or injunction for violations of the FFDC Act without further notice. Firms that fail to take corrective action may also be referred to FDA's Office of Criminal Investigations for possible criminal prosecution for violations of the FFDC Act
and other federal laws.


FDA is advising consumers not to purchase or use H1N1 Flu Virus-related products offered for sale that have not been approved, cleared, or authorized by FDA. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning marketing unapproved, uncleared, and unauthorized H1N1 Flu Virus-related products in violation of the FFDC Act. This list can be found at http://www.accessdata.fda.gov/scripts/h1n1flu/. Once the violative claims and/or products have been removed from your website, and these corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate corrective action.


If you are not located in the United States, please note that unapproved, uncleared, or unauthorized products intended to diagnose, mitigate, prevent, treat, or cure the H1N1 Flu Virus offered for importation into the United States are subject to detention and refusal of admission. We will advise the appropriate regulatory or law enforcement officials in the country from which you operate that FDA considers your product(s) listed above to be unapproved, uncleared, or unauthorized products that cannot be legally sold to consumers in the United States. Please direct any inquiries concerning this letter to FDA at FDAFLUTASKFORCECDER@fda.hhs.gov or by contacting Sarah E. Burrell at (301) 796-4283.



Sincerely,


Deborah M. Autor, Esq.
Director
Office of Compliance
Center for Drug Evaluation and Research


CC:


Nozin LLC
2100 Ponce De Leon Blvd., Suite 901
Coral Gables, FL 33134


Nozin LLC
230 Harbor Dr.
Key Biscayne, FL 33169


Nozin LLC
PO Box 70663
Chevy Chase, MD 20813


kwalsh@nozin.com


Kevin Walsh
Global Life Technologies
P.O. Box 144357
Coral Gables, FL 33134-4357